Literature DB >> 3348605

In vitro activities of LY163892, cefaclor, and cefuroxime.

C C Knapp1, J A Washington.   

Abstract

The in vitro activity of LY163892, a synthetic oral cephalosporin, was compared with those of cefaclor and cefuroxime against 1,193 clinical isolates. MIC ranges and MICs for 50 and 90% of isolates of the three cephalosporins were comparable. The activities of LY163892 and cefaclor were, however, highly inoculum dependent against beta-lactamase-positive Haemophilus influenzae and Staphylococcus aureus; that of cefuroxime was not. LY163892 and cefuroxime appeared stable in microdilution trays stored at 5 and -20 degrees C for 5 weeks, in contrast to cefaclor which remained stable for more than a week only at -5 degrees C.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3348605      PMCID: PMC172113          DOI: 10.1128/AAC.32.1.131

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  Cefuroxime, a beta-lactamase-resistant cephalosporin with a broad spectrum of gram-positive and -negative activity.

Authors:  H C Neu; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1978-04       Impact factor: 5.191

2.  Stability and blood level determinations of cefaclor, a new oral cephalosporin antibiotic.

Authors:  M A Foglesong; J W Lamb; J V Dietz
Journal:  Antimicrob Agents Chemother       Date:  1978-01       Impact factor: 5.191

3.  Comparison of in vitro activity of cephalexin, cephradine, and cefaclor.

Authors:  N J Bill; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1977-03       Impact factor: 5.191

4.  Cefuroxime - a new cephalosporin antibiotic.

Authors:  C H O'Callaghan; R B Sykes; D M Ryan; R D Foord; P W Muggleton
Journal:  J Antibiot (Tokyo)       Date:  1976-01       Impact factor: 2.649

5.  Pharmacology of Cefuroxime as the 1-acetoxyethyl ester in volunteers.

Authors:  S M Harding; P E Williams; J Ayrton
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

6.  Comparative beta-lactamase resistance and antistaphylococcal activities of parenterally and orally administered cephalosporins.

Authors:  W E Farrar; N M O'Dell
Journal:  J Infect Dis       Date:  1978-04       Impact factor: 5.226

7.  Influence of beta-lactamase-producing strains of Branhamella catarrhalis and Haemophilus influenzae on certain beta-lactam antibiotics.

Authors:  J Johnsson; J E Brorson
Journal:  J Antimicrob Chemother       Date:  1983-09       Impact factor: 5.790

8.  Cefaclor: in vitro spectrum of activity and beta-lactamase stability.

Authors:  H C Neu; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1978-04       Impact factor: 5.191

  8 in total
  15 in total

1.  In vitro activity and beta-lactamase stability of LY163892.

Authors:  E Pelosi; R Fontana
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-08       Impact factor: 3.267

2.  Influence of storage and susceptibility test conditions on stability and activity of LY163892 and four other cephalosporins.

Authors:  J H Jorgensen; J S Redding; L A Maher
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

3.  Loracarbef versus cefaclor in the treatment of urinary tract infections in women.

Authors:  A Iravani
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

Review 4.  Loracarbef. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  R N Brogden; D McTavish
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

5.  Comparative in vitro activities of several new fluoroquinolones and beta-lactam antimicrobial agents against community isolates of Streptococcus pneumoniae.

Authors:  T Mazzulli; A E Simor; R Jaeger; S Fuller; D E Low
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

6.  Prophylaxis with oral cefadroxil versus intravenous cefuroxime in trochanteric fracture surgery. A clinical multicentre study.

Authors:  K S Nungu; C Olerud; L Rehnberg; S Larsson; P Nordell; I Allvin; S Bengtsson; L Wallinder; G Hedin
Journal:  Arch Orthop Trauma Surg       Date:  1995       Impact factor: 3.067

7.  Effectiveness of short-course therapy (5 days) with cefuroxime axetil in treatment of secondary bacterial infections of acute bronchitis.

Authors:  D Henry; G E Ruoff; J Rhudy; A Puopolo; M Drehobl; J Schoenberger; G Giguere; J J Collins
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

8.  Loracarbef versus penicillin V in the treatment of streptococcal pharyngitis and tonsillitis.

Authors:  O Müller; Z Spirer; K Wettich
Journal:  Infection       Date:  1992 Sep-Oct       Impact factor: 3.553

9.  Pharmacokinetics of loracarbef and interaction with acetylcysteine.

Authors:  S Roller; H Lode; I Stelzer; K M Deppermann; M Boeckh; P Koeppe
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-09       Impact factor: 3.267

10.  Comparison of loracarbef (LY163892) versus amoxicillin in the treatment of bronchopneumonia and lobar pneumonia.

Authors:  O Müller; K Wettich
Journal:  Infection       Date:  1992 May-Jun       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.